83 results
SC 13E3/A
EX-99
STSA
Satsuma Pharmaceuticals Inc
8 Jun 23
Going private transaction (amended)
9:16am
Benefits of Agreement
Governing Law
Exclusive Jurisdiction
Waiver of Jury Trial
Legal Holidays
Severability
Expiration
Construction
Confidentiality
Further … registered in the CVR Register will be the valid obligations of Parent, evidencing the same right and will entitle the transferee to the same benefits
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
18 May 23
January 2024 PDUFA date expected
4:20pm
), administered via Satsuma’s proprietary nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
title, salary, duties, benefits, etc.
Purchase Order No. 0003
Pursuant to the Purchase Order No. 0003, Parent supplied 5 products i.e., (i) Fit … ) terminate the Company ESPP prior to the Effective Time.
Executive Officer Change in Control Severance Benefits
The Company has entered into Change
10-K/A
koucekpa58wgmme8ukpn
28 Apr 23
Annual report (amended)
4:08pm
8-K
EX-10.1
eza4q
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-2.1
6rurzi3p0 ds5pd9tq
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-2.2
zwfn8i9
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-99.1
va80u1pj97
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-99.1
85o18sew2b8du bx
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.2
fks suor0f
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
tbeu8j
30 Nov 22
Other Events
4:00pm
8-K
EX-99.1
d4gg24 dk8d
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
8-K
EX-1.1
7idxpt746um4ic0ls9
3 Nov 22
Entry into a Material Definitive Agreement
4:45pm
424B5
wmupzpqc p9a5
3 Nov 22
Prospectus supplement for primary offering
4:42pm
8-K
EX-99.1
1vg9mhp3zon ym
3 Nov 22
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:00pm
8-K
EX-99.1
uj9eazylwub63
20 Sep 22
Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial
5:03pm